These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220 [TBL] [Abstract][Full Text] [Related]
3. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725 [TBL] [Abstract][Full Text] [Related]
4. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441 [TBL] [Abstract][Full Text] [Related]
5. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064 [TBL] [Abstract][Full Text] [Related]
6. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Ben Sahra I; Regazzetti C; Robert G; Laurent K; Le Marchand-Brustel Y; Auberger P; Tanti JF; Giorgetti-Peraldi S; Bost F Cancer Res; 2011 Jul; 71(13):4366-72. PubMed ID: 21540236 [TBL] [Abstract][Full Text] [Related]
7. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742 [TBL] [Abstract][Full Text] [Related]
8. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Janjetovic K; Vucicevic L; Misirkic M; Vilimanovich U; Tovilovic G; Zogovic N; Nikolic Z; Jovanovic S; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L Eur J Pharmacol; 2011 Jan; 651(1-3):41-50. PubMed ID: 21114978 [TBL] [Abstract][Full Text] [Related]
9. Interaction of glibenclamide and metformin at the level of translation in pancreatic β cells. Wang Q; Cai Y; Van de Casteele M; Pipeleers D; Ling Z J Endocrinol; 2011 Feb; 208(2):161-9. PubMed ID: 21084384 [TBL] [Abstract][Full Text] [Related]
10. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Zakikhani M; Blouin MJ; Piura E; Pollak MN Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346 [TBL] [Abstract][Full Text] [Related]
11. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. Cai H; Zhang Y; Han TK; Everett RS; Thakker DR Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo anti-melanoma action of metformin. Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981 [TBL] [Abstract][Full Text] [Related]
13. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Sreekanth CN; Bava SV; Sreekumar E; Anto RJ Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920 [TBL] [Abstract][Full Text] [Related]
14. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500 [TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase. Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093 [TBL] [Abstract][Full Text] [Related]
17. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734 [TBL] [Abstract][Full Text] [Related]
18. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450 [TBL] [Abstract][Full Text] [Related]
19. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343 [TBL] [Abstract][Full Text] [Related]
20. Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Zhang CX; Pan SN; Meng RS; Peng CQ; Xiong ZJ; Chen BL; Chen GQ; Yao FJ; Chen YL; Ma YD; Dong YG Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):55-62. PubMed ID: 21083698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]